MannKind is a biotechnology business based in the US. MannKind shares (MNKD) are listed on the NASDAQ and all prices are listed in US Dollars. MannKind employs 411 staff and has a trailing 12-month revenue of around $224.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.74 |
|---|---|
| 52-week range | $3.17 - $6.04 |
| 50-day moving average | $4.95 |
| 200-day moving average | $4.20 |
| Wall St. target price | $7.08 |
| PE ratio | 142.75 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.74 from 2024-07-22
| 1 week (2024-07-17) | -1.03% |
|---|---|
| 1 month (2024-06-24) | 5.71% |
| 3 months (2024-04-24) | 36.99% |
| 6 months (2024-01-24) | 67.35% |
| 1 year (2023-07-24) | 29.57% |
|---|---|
| 2 years (2022-07-22) | 72.37% |
| 3 years (2021-07-23) | 31.35% |
| 5 years (2019-07-24) | 407.96% |
Valuing MannKind stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MannKind's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MannKind's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 143x. In other words, MannKind shares trade at around 143x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
MannKind's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $35.8 million.
The EBITDA is a measure of a MannKind's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $224.6 million |
|---|---|
| Operating margin TTM | 23.13% |
| Gross profit TTM | $42.3 million |
| Return on assets TTM | 4.97% |
| Return on equity TTM | 0% |
| Profit margin | 3.78% |
| Book value | $-0.85 |
| Market Capitalization | $1.6 billion |
TTM: trailing 12 months
We're not expecting MannKind to pay a dividend over the next 12 months.
MannKind's shares were split on a 1:5 basis on 2 March 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MannKind shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for MannKind shares which in turn could have impacted MannKind's share price.
Over the last 12 months, MannKind's shares have ranged in value from as little as $3.17 up to $6.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MannKind's is 1.318. This would suggest that MannKind's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S. A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.